Quantcast
Last updated on April 18, 2014 at 13:07 EDT

Latest Monoclonal antibody therapy Stories

2014-02-18 08:32:37

BURNABY, BC, Feb. 18, 2014 /PRNewswire/ - Innovative Targeting Solutions Inc. (ITS) a pioneer in novel protein engineering technologies, today announced the successful application of the company's proprietary affinity maturation technology for the purposes of generating antibodies with pM affinities. These first in class antibodies are unique in that all mutations are specifically targeted to CDRs, unlike error prone PCR, somatic hypermutation or other traditional mutagenesis...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2014-01-13 04:21:01

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody(TM) research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept...

2014-01-10 08:23:51

First-in-class program for the treatment of atopic dermatitis and allergic diseases SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the development of a first-in-class therapeutic antibody to interleukin-33 (IL-33). Discovered using the Company's proprietary SHM-XEL platform, AnaptysBio's anti-IL-33 lead candidate antibody (ANB020) inhibits IL-33 cytokine function by blocking interaction with its receptor at...

2014-01-07 08:31:00

Lam Joins KaloBios with Over 28 Years Biopharmaceutical Manufacturing Experience SOUTH SAN FRANCISCO, Calif., Jan. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he ultimately served as Global Head of Contract Manufacturing Operations, Commercial Drug...

2013-12-17 08:29:17

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target. Under this agreement, Momenta will pay an upfront fee to AnaptysBio in exchange for an option to acquire antibodies generated by AnaptysBio using its SHM-XEL platform against a specific...

2013-12-17 04:20:55

BREDA, The Netherlands and GHENT, Belgium, December 17, 2013 /PRNewswire/ -- Dose confirmed for Phase Ib safety and efficacy expansion study arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable...

2013-12-16 04:21:30

LONDON and BOSTON, December 16, 2013 /PRNewswire/ -- Biased Agonist Antibodies Generated To G Protein-Coupled Receptor Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces the publication of a new scientific paper describing the use of StaR(R) proteins (thermostabilised G protein-coupled receptors, GPCRs) as antigens for antibody drug discovery. StaR proteins based on the beta1-adrenergic (beta1AR) receptor were...

2013-11-07 23:30:39

RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store. Dallas, TX (PRWEB) November 07, 2013 The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of...

2013-11-07 04:24:12

THOUSAND OAKS, Calif., Nov. 7, 2013 /PRNewswire/ -- ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies. "ImmunGene, run by...